SecBot SecBot
8-K ·Filed Nov 5, 2026

KROS

Keros Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed11d 10h ago SEC0001664710-26-000067
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor for initial Phase 2 rinvatercept data in DMD expected in H1 2027 and regulatory engagement for the ALS trial design. The Takeda partnership milestones for elritercept remain a key value driver.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

KROS drug pipeline →

rinvatercept

● Neutral Named in this 8-K
Impact
Phase
Phase 2
Time to market
Unknown — the drug is in Phase 2 for DMD with initial data expected H1 2027. If successful, Phase 3 trials and regulatory filing would follow, putting potential approval several years away (likely 2029-2031 at the earliest).
Next catalyst
None dated

What to watchWatch for the Phase 2 DMD initial data readout for rinvatercept expected in H1 2027, and any regulatory engagement updates for the ALS program in H2 2026. The stock trades at ~$11.23 with analyst mean price target of ~$19.83 (69% upside), but the stock is 18.8% below its 200-day SMA, reflecting the pre-revenue, binary-risk profile typical of clinical-stage biotechs.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$9.36
T+0 close · Nov 5, 2026 · via day close
Latest settled
+10.04%
T+5 · $10.30 · next T+20 in 20d
Vs SPY
+7.45%
α at T+5
Latest observation
+8.27%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $9.36entry
  2. T+1 · 8d ago −2.03%α −4.40% · $9.17
  3. T+5 · 4d ago +10.04%α +7.45% · $10.30
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Keros Therapeutics filed an 8-K to update its corporate presentation, which is used in investor meetings. The presentation highlights progress with rinvatercept (KER-065) in Duchenne muscular dystrophy (Phase 2 trial commenced, data expected H1 2027) and amyotrophic lateral sclerosis (Phase 2 trial design planned), and KER-206 in osteoporosis (nonclinical). No new financial data or material events were disclosed.

Key Facts

  • Keros updated its corporate presentation for investor meetings on November 5, 2026.
  • Phase 2 basket trial for rinvatercept in DMD has commenced; initial data expected in H1 2027.
  • Keros plans to engage regulators on a Phase 2 trial design for rinvatercept in ALS in H2 2026.
  • KER-206, a nonclinical asset, showed reversal of bone loss in a mouse model of osteoporosis.
  • Elritercept (KER-050) is licensed to Takeda, which is conducting three Phase 3 trials.
  • No financial results, guidance, or material agreements were disclosed in this filing.

Financial Impact

No financial figures disclosed; the filing is a routine corporate presentation update.

Risk Factors

  • Rinvatercept is in early-stage clinical development with no approved products; clinical trial risks are high.
  • Keros has a limited operating history and historical losses; may need additional funding.
  • Competition from other muscle-targeted therapies (e.g., apitegromab) and gene therapies for DMD.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001664710-26-000067
Document: keros-corporatepresentat.htm0001664710-26-000067
Document: 0001664710-26-000067-index-headers.html0001664710-26-000067
Document: 0001664710-26-000067-index.html0001664710-26-000067
Document: 0001664710-26-000067.txt0001664710-26-000067

Track record

27 reports on KROS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
  3. Nov 5, 202611d ago 8-K Neutral 3/10 Viewing Entry $9.36 Now $10.03 +7.16% settles Dec 7
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  5. Nov 5, 202611d ago Press Release Neutral 5/10 No price data
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
  7. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
  8. Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  9. Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  10. Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens in 6h 9m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026